$0.10
+0.00 (+0.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ZVSA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 0 tracked-famous managers · FINRA short interest 7.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney DiseaseNCT06489340Percent change in 24-hour urinary albumin to creatinine ratio (UACR)Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Withdrawn due to patient enrollment challenges | Drug: 2HPβCD | Diabetic Kidney Disease | 0 | 2026-08-11 | 2025-11-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19